Toward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies

Article Figures & Data

TABLE 1.

Main Results of Published ICI Radiolabeled PET Imaging Studies

Clinical trial	Imaging technique	Tumor type	Patients (n)	Results
Niemeijer et al. (9) (NCT03065764)	⁸⁹Zr-pembrolizumab PET	Non–small cell lung cancer	12	⁸⁹Zr-pembrolizumab PET is feasible and safe; ⁸⁹Zr-pembrolizumab uptake is higher in patients with treatment response; ⁸⁹Zr-pembrolizumab uptake did not correlate with PD-1/PD-L1 expression
Bensch et al. (10) (NCT02453984)	⁸⁹Zr-atezolizumab PET	Locally advanced or metastatic solid tumors	22	⁸⁹Zr-atezolizumab PET is feasible and safe; ⁸⁹Zr-atezolizumab uptake correlates with PD-L1 expression; ⁸⁹Zr-atezolizumab SUV_max predicts response to atezolizumab, including overall and progression-free survival, better than PD-L1 expression assessed by immunohistochemistry
Niemeijer et al. (11) (2015-004760-11)	¹⁸F-PD-L1 PET; ⁸⁹Zr-nivolumab PET	Non–small cell lung cancer	13	¹⁸F-PD-L1 and ⁸⁹Zr-nivolumab PET is feasible and safe; ¹⁸F-PD-L1 uptake correlates with tumor PD-L1 expression; ⁸⁹Zr-nivolumab uptake correlates to PD-1 expression on lymphocytic aggregates; ⁸⁹Zr-atezolizumab SUV_peak correlates with treatment response (responders vs. nonresponders based on RECIST, version 1.1)